Matt Winchester, Director of Renal Pharma, explains the decision to join:
"This is a critical time for the UK pharmaceutical industry, and it is important that all companies are working together and moving in the same direction. The industry is changing, and the support the ABPI provides is even more valuable now than ever before."
Stephen Whitehead, Chief Executive of the ABPI, welcomed FMC's decision:
"I'm delighted that Fresenius Medical Care, with such a depth of experience in supporting patients, has joined the ABPI. The ABPI is the voice of the research-based industry in the UK and our partnership work with the NHS brings real benefits to patients. We are very proud that they have chosen to come on board with the ABPI."
Fresenius Medical Care has been caring for NHS kidney patients in the UK for over 20 years, as both a manufacturer of dialysis products and equipment, and as a service provider working in partnership with the NHS. FMC supplies dialysis products and renal pharmaceutical products to over 10,000 patients’ homes. The company also operates 54 NHS dialysis clinics providing high quality care for almost 4,000 patients in the UK.
ABPI Press Office
Tel: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441
Mobile: +44 (0) 7808 641810 or +44 (0) 7850 312064
Notes to editor
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.